Multi-phase Microfluidic Devices for Characterization of Circulating Tumor Cells

用于表征循环肿瘤细胞的多相微流体装置

基本信息

批准号：
8658772
负责人：
John Zhong
金额：
$ 9.92万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-05-01 至 2017-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8658772
关键词：
Affect Biochemical Biological Biological Models Bioreactors Blood Breast Cancer Cell Breast Cancer Treatment Cancer Patient Cell Separation Cells Characteristics Clinical Colorectal Cancer Complementary DNA Cytolysis Development Devices Diagnostic Procedure Disease Progression Docking ERBB2 gene Electrodes Encapsulated Evaluation FDA approved Fluorescence Flushing Gene Amplification Gene Expression Gene Expression Profile Gene Expression Profiling Grant Hela Cells Heterogeneity Hospitals Individual Laboratories Malignant Neoplasms Malignant neoplasm of prostate Medicine Microfluidic Microchips Microfluidics Molecular Molecular Analysis Molecular Profiling Monitor Mutation Neoplasm Circulating Cells Neoplasm Metastasis Oils Optics Patients Phase Physicians Prevalence Primary Neoplasm Process Reverse Transcription System Technology Testing Trastuzumab Travel United States Food and Drug Administration base cancer diagnosis cancer therapy cell analyzer clinical application design insight malignant breast neoplasm nanolitre novel operation outcome forecast prototype success tool tumorigenesis

项目摘要

DESCRIPTION (provided by applicant): Multi-phase Microfluidic Devices for Characterization of Circulating Tumor Cells in Breast Cancer Oncogenesis is a multi-step process leading to a variety of genetic changes with alterations in the transcriptome, and adaptive changes responding to treatments. Therefore, monitoring the dynamic alteration of cancer is critical for cancer treatment. We have integrated multiple microfluidic modules developed in our R21 into a Multi-Phase Single Cell Analyzer (MSCA) for circulating tumor cells (CTC) enumeration and single CTC characterization. Combining the robustness of microstructure, preciseness of optical manipulation and mobility of droplet, the integrated MSCA isolates and encapsulates individual CTC into droplets for nanoliter molecular analysis. With the ability to characterize CTC in routine blood draws, the integrated platform will transform the minimal invasive CTC assessment into a powerful tool for cancer treatment evaluation in hospitals and clinical laboratories, and realize personalized medicine for cancer treatment.

描述（由申请人提供）：用于表征乳腺癌肿瘤中循环肿瘤细胞的多相微流体设备是一个多步骤过程，导致转录组发生变化以及适应性变化对治疗的反应，导致各种遗传变化。因此，监测癌症的动态改变对于癌症治疗至关重要。我们已经将R21中开发的多个微流体模块整合到了多相单细胞分析仪（MSCA）中，以进行循环肿瘤细胞（CTC）枚举和单个CTC表征。结合了微观结构的鲁棒性，光学操纵的精确性和液滴的迁移率，集成的MSCA分离株并将单个CTC封装到液滴中，以进行纳米级分子分析。具有在例程中表征CTC的能力抽血，集成平台将将最小的侵入性CTC评估转变为医院和临床实验室中癌症治疗评估的强大工具，并实现个性化的癌症治疗药物。